Translational team-up
September 2017

SEATTLE—Adaptive Biotechnologies has launched a translational collaboration with the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) with the aim of using Adaptive’s immunoSEQ Platform to increasingly include T cell and B cell receptor sequencing into NCI-sponsored clinical trials. The organizations hope to use the platform to more accurately measure and track immune repertoire dynamics that could influence patients’ response to different cancer immunotherapies.
“We are delighted to announce our engagement with NCI,” said Chad Robins, CEO and founder of Adaptive Biotechnologies. “It’s our goal to support NCI investigators by enriching their research and expertise in immune correlative data generation with Adaptive’s immunoSEQ Platform, and to help expedite the development of new immune molecular biomarkers that inform the next wave of novel therapies and rational combinations.”

1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.